Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tamir Biotech Selects CRO | Contract Pharma

What are you searching for?

Sign in
Breaking News

Tamir Biotech Selects CRO

Pharmatech Oncology to help run Phase II Ranpirnase trial

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Tamir Biotechnology (formerly known as Alfacell Corp.) has selected Pharmatech Oncology, Inc. as the CRO to run its upcoming Phase II trial of Ranpirnase (Onconase) in combination with platinum doublet chemotherapy for patients with advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC). Complete patient accrual is expected in 12 months, with multiple centers participating in the trial.

Pharmatech Oncology is based out of Denver, CO and has extensive experience conducting oncology clinical trials. Pharmatech’s responsibilities include patient enrollment, data management, clinical monitoring, statistical analysis, and FDA regulatory filings.

The selection process began in April 2010, when the company invited several CROs to file RFPs for the Phase II NSCLC trial. The initial pool was whittled down to six companies “deemed to be responsive to our RFP,” read a Tamir statement. Pharmatech Oncology was chosen based on “experience, competitive pricing, ability to deliver the goods and services requested within the specified times, as well as their clear understanding of the trial design and protocol,” said the company.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics